The PE Ratio as of November 2024 (TTM) for Ultragenyx Pharmaceutical Inc. (RARE) is -7.44

According to Ultragenyx Pharmaceutical Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.44. This represents a change of -2.00% compared to the average of -7.59 of the last 4 quarters.

Ultragenyx Pharmaceutical Inc. (RARE) Historical PE Ratio (quarterly & annually)

How has RARE PE Ratio performed in the past?

The mean historical PE Ratio of Ultragenyx Pharmaceutical Inc. over the last ten years is -15.23. The current -7.44 PE Ratio has changed 4.78% with respect to the historical average. Over the past ten years (40 quarters), RARE's PE Ratio was at its highest in in the June 2020 quarter at 46.34. The PE Ratio was at its lowest in in the December 2020 quarter at -93.20.

Ultragenyx Pharmaceutical Inc. (RARE) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Ultragenyx Pharmaceutical Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Ultragenyx Pharmaceutical Inc. (RARE) Average PE Ratio

How has RARE PE Ratio performed in the past?

The current PE Ratio of Ultragenyx Pharmaceutical Inc. (RARE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Ultragenyx Pharmaceutical Inc. (RARE) PE Ratio vs. Peers

How is RARE’s PE Ratio compared to its peers?

Ultragenyx Pharmaceutical Inc.’s PE Ratio is less than X4 Pharmaceuticals, Inc. (-4.05), less than Terns Pharmaceuticals, Inc. (-5.12), greater than Day One Biopharmaceuticals, Inc. (-15.73), less than PDS Biotechnology Corporation (-1.90), less than Inozyme Pharma, Inc. (-1.84), greater than Mirati Therapeutics, Inc. (-11.26), less than Amylyx Pharmaceuticals, Inc. (-1.38), greater than Apellis Pharmaceuticals, Inc. (-15.24), greater than Crinetics Pharmaceuticals, Inc. (-16.16), less than Arvinas, Inc. (-6.04), greater than Revolution Medicines, Inc. (-16.70), less than Kura Oncology, Inc. (-4.75), less than Acumen Pharmaceuticals, Inc. (-1.74), less than Incyte Corporation (425.32), greater than Alnylam Pharmaceuticals, Inc. (-94.78), less than United Therapeutics Corporation (14.97),

Build a custom stock screener for Ultragenyx Pharmaceutical Inc. (RARE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ultragenyx Pharmaceutical Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Ultragenyx Pharmaceutical Inc. (RARE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Ultragenyx Pharmaceutical Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.